F11 and Thromboembolism: By comparing these results with the effect of the three SNPs on aPTT (Supplementary Table 1), our study suggests that, among the three factors tested, targeting FXI may yield the best compromise between thromboembolism risk reduction and increased bleeding liability, which is consistent with the outcomes of a recent phase 2 clinical trial42.